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In medicine, superparamagnetic nanoparticles bound to chemotherapeutics are currently investigated for their feasibility in local
tumor therapy. After intraarterial application, these particles can be accumulated in the targeted area by an external magnetic ﬁeld
to increase the drug concentration in the region of interest (Magnetic-Drug-Targeting). We here present an analytical method
(HPLC-UV), to detect pure or ferroﬂuid-bound mitoxantrone in a complex matrix even in trace amounts in order to perform
biodistribution studies. Mitoxantrone could be extracted in high yields from diﬀerent tissues. Recovery of mitoxantrone in liver
tissue (5000ng/g) was 76 ± 2%. The limit of quantiﬁcation of mitoxantrone standard was 10ng/mL ±12%. Validation criteria
such as linearity, precision, and stability were evaluated in ranges achieving the FDA requirements. As shown for pilot samples,
biodistribution studies can easily be performed after application of pure or ferroﬂuid-bound mitoxantrone.
1.Introduction
Application of chemotherapeutic agents bound to magnetic
nanoparticles is a promising approach for site speciﬁc drug
deposition. Magnetic-Drug-Targeting (MDT) is intended to
elevate the drug concentration in the region of interest,
because the drug loaded particles are enriched by a focused
external magnetic ﬁeld to deﬁned body compartments after
application [1–4]. This method can lead to both higher
potency of antitumor treatments and reduction of negative
side eﬀects. In our model, drug loading was realized with
mitoxantrone (MTO) (Figure 1), an anthracendion deriva-
tive which inhibits the DNA and RNA synthesis and causes
DNA strand breaks by intercalation [5, 6]. This active com-
ponent was adsorptively bound to the iron oxide nanopar-
ticles. This agent is used extensively in clinical trials to treat
fatal diseases including leukemia, lymphoma, cancers of the
breast and prostate [7], and to treat multiple sclerosis [8, 9].
A quantitative determination of the biodistribution of
magnetic nanoparticles can be achieved by magnetorelax-
ometry. The applicability of this technique for the quantiﬁ-
cation of ferroﬂuids (FF) in tissue has been demonstrated
previously for an extracted tumor slice model [10], a speciﬁc
artery model [11], and is even in process for the whole body
distribution. MTO enrichment might be diﬀerent, so we are
interested in developing an easy multifunctional method to
quantify the amount of MTO, especially if it is bound to
coated nanoparticles.
Various methods have been described to extract MTO
from blood plasma [12–16]a n dt i s s u e s[ 17]o ni t so w n .
Moreover there are established protocols to determine
MTO by HPLC measurements in context of drug delivery
systems like liposome carriers [18] and nanosphere vehicles
[19]. Protein precipitation with 0.5M hydrochloric acid:
acetonitrile (90:10, v/v), as described by Johnson et al. [18],
leads to a recovery of pure MTO in porcine muscle tissue
of more than 85% (Table 1). Nevertheless, measurement of
MTO bound to iron oxide nanoparticles is more diﬃcult,
and extracting whole organs of white New Zealand rabbits
this way was unfeasible.2 Journal of Biomedicine and Biotechnology
Table 1: Extraction of porcine muscle and liver tissues containing pure mitoxantrone (MTO) or MTO bound to ferroﬂuid (FF). The Table
shows the high recovery rate of pure MTO and a lower recovery rate of FF-bound MTO in diﬀerent tissues.
Sample Extraction modality(1) Recovery [%](2)
2g liver/100μgM T O 2 × MeOH: 1N HCl = 50:50 96 ±10
1g muscle tissue/100μgM T O 2×0,5 HCl 74(3)
1g muscle tissue/100μgM T O 2 × MeCN: 0,5N HCl 10:90 85 ±9
1g muscle tissue/100μgM T O 2 × MeOH:1N HCl = 50:50 87 ±9
2g muscle tissue/100μg MTO + 500μLF F 2 × MeOH: 1N HCl = 50:50 64 ±7
1g muscle tissue/100μg MTO + 500μLF F 2 × MeCN: 0,5N HCl 10:90 79 ±8
2.5g liver/100μgM T O+1m LF F 2 × MeOH: 1N HCl = 50:50 56 ±27
2.5g liver/100μgM T O+1m LF F 2 × MeCN: 1N HCl = 10:90 58 ±15
(1)Typical extraction procedure: double incubation in ultrasonic bath, each for 10 minutes. Collecting the supernatant after centrifugation and HPLC-
measurement afterwards.
(2)number of independent experiments n = 3
(3)single experiment.
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Figure 1: Structure of mitoxantrone (MTO).
Lu et al. developed a helpful method to determine MTO
[19], which has been applied in the form of bovine serum
albumin (BSA) nanospheres and revealed also promising
results in our context. But in order to reliably capture even
trace amounts of MTO, an optimization of the extraction
mode has been necessary, as well as the development of a
subsequent solid phase extraction (SPE) method. Here we
present a newly developed method to determine MTO in
diﬀerent tissues and of diﬀerent binding statuses.
2. Experimental
2.1. Chemicals. The analytical grade solvent, methanol, ace-
tonitrile, chloroform were obtained from Carl Roth, Ger-
many and Merck, Germany. Other chemicals were either
delivered by Merck, Germany (formic acid, sodium formate,
phosphoric acid, potassium dihydrogen phosphate, and cit-
ric acid), Carl Roth, Germany (trichloroacetic acid and so-
dium citrate dihydrate), or Sunlife, Germany (ascorbic acid).
MTO was delivered by NeoCorp Pharma (Lot: 82056305,
expiration date: 05/2010), Germany (test sample, a concen-
trate (2mg/mL) to produce an injection solution).
The ferroﬂuids were synthesized according to a protocol
by Hodenius [20].
2.2. HPLC. The HPLC analyses were performed by a Waters
Alliance model consisting of a separation module (2695
series) and a dual wavelength absorbance detector (2487
series). The eluate was monitored at 254nm. The separation
was carried out using a 3.0 × 100mm X-Bridge Phenyl
column (Waters, Germany) with a particle diameter of
3.5μm; the guard column consisted of the same material and
was 3.0 ×20mm of size. The column temperature was 55◦C,
the mobile phase was made up of buﬀer (80nM sodium
formate and formic acid, pH 3.0) and methanol (80:20v/v).
Flow was 1mL/min, the injection volume was 50μLa t
room temperature. All measurements were performed after
an HPLC-method validation including selectivity, linearity,
limitofquantiﬁcation,precision,accuracy,recoveryrate,and
stability according to a validation protocol [21, 22]. Prior to
the sample measurements, a calibration curve with MTO-
concentrations of 10ng/mL–20000ng/mL was done.
2.3. Method Development/Optimization. For the extraction
experiments, we used porcine muscle tissue and liver
tissue which were doped with deﬁned amounts of pure
MTO or MTO bound to FF. This occurred by adding
dissolved MTO at deﬁned values (see Tables 1 and 2)
to tissue homogenates and incubating overnight at room
temperature. Due to the complexity of liver tissue and
the successful determination here and moreover in muscle
tissue, this method could be suitable to perform a complete
biodistribution of MTO in rabbits. The extraction was a
result of an optimization process. Liver or muscle tissue,
doped with MTO, was homogenized for 1 minute using
an Ultra Turrax apparatus (Ika, Staufen, Germany) to lyse
the cell membranes prior to sonication. Several extraction
mixtures containing hydrochloric acid or phosphoric acid
in combination with MeOH were tested for extraction
eﬃciency and their compatibility with the SPE procedures
(see Tables 1 and 3). For the extraction, simple shaking for 4
or 24 hours was compared to vortex mixing and 1 to 4-fold
ultrasonic treatment with a duration of 1 hour each using
an ultrasonic bath (US) (Bandelin Sonorex TK 52, Berlin,
Germany, without temperature control) (Table 2).
Analternativelyperformedacceleratedsolventextraction
(ASE) was done with ASE 200 (Dionex, Idstein, Germany) at
temperatures of 40◦Ca n d8 0 ◦C according to a protocol ofJournal of Biomedicine and Biotechnology 3
Table 2: Comparison of diﬀerent extraction techniques.
Matrix(1) Extraction mode(2) Recovery [%](3)
MTO + 0.5g porcine liver 1 fold vortexing 3 minutes 22 ±4
FF-MTO + 0.5g porcine liver 1 fold vortexing 3 minutes 26 ±4
FF-MTO + 0.5g porcine liver 1 fold vortexing 3 minutes + 5 minutes Ultrasound 34 ±3
FF-MTO + 0.5g porcine liver 4 hours shaking (Thermomixer Eppendorf Comfort 600rpm) 27 ±2
FF-MTO + 0.5g porcine liver 24 hours shaking (Thermomixer Eppendorf Comfort 600rpm) 18(4)
FF-MTO + 0.5g porcine liver 1 ×1 hour Ultrasound 38 ±3
FF-MTO + 0.5g porcine liver 1 ×4 hours Ultrasound 31 ±5
FF-MTO + 0.5g porcine liver 4 ×1 hour Ultrasound 76 ±6
FF-MTO + 5g porcine liver ASE(5) 40◦C, 1 cycle 36 ±6
FF-MTO + 5g porcine liver ASE(5) 80◦C, 1 cycle 81 ±6
(1)MTO-amount added to the tissue homogenate samples: 25μg MTO, ferroﬂuid amount (FF): 1mL
(2)Extraction solution: 500μLw a t e r ,5 0μLa s c o r b i ca c i d( 2 0 % )i nc i t r a t eb u ﬀer (pH 3.0), 200μL MeOH, 200μL formic acid, 100μL 20% trichloroacetic acid,
400μL chloroform.
(3)number of independent experiments n = 3p e r f o r m e do n3d i ﬀerent days
(4)single experiment
(5)ASE= Accelerated solvent extraction: solvent composition: 20%(v/v) MeOH, 20%(v/v) formic acid, 10%(v/v) trichloroacetic acid (20%), 50%(v/v)
chloroform.
Table 3: Mitoxantrone (MTO) recovery of pure MTO or MTO bound to ferroﬂuid (FF) in 2.5g tissue using a RP-18-Cartridge. 1st section
showsextractantsbasedonhydrochloricacid,2ndsectionshowsphosphoricacid-basedextractants,and3rdsectionshowsphosphate-buﬀer
extractants. In general: FF-bound MTO in liver tissue exhibited insuﬃcient recovery rates.
Cartridge Matrix Extraction mode(3) Condition/Elution-
mode Recovery [%](1)
No cartridge FF-MTO 1 N HCl No cartridge 93(2)
Sep-Pak-Plus C18 MTO 1 N HCl 1 N HCl/MeOH 77 ±6
1st Sep-Pak-Plus C18 MTO + porcine muscle
tissue 1NH C l H 2O/MeOH 67 ±2
Sep-Pak-Plus C18 MTO + porcine liver 1 N HCl 1 N HCl/MeOH 41 ±11
Sep-Pak-Plus C18 FF-MTO 1 N HCl 1 N HCl/MeOH 4 ±1
Sep-Pak-Plus C18 FF-MTO + porcine liver 1 N HCl 1 N HCl/MeOH 9 ±8
No Cartridge FF-MTO 0.1M H3PO4 No Cartridge 94(2)
2nd Sep-Pak-Plus C18 FF-MTO 0.1M H3PO4 1 N HCl/MeOH 74 ±10
Sep-Pak-Plus C18 MTO + porcine liver 0.1M H3PO4 0,1M H3PO4/MeOH 76 ±10
Sep-Pak-Plus C18 FF-MTO + porcine liver 0.1M H3PO4 MeOH/0, 1M H3PO4 12 ±8
3rd Sep-Pak-Plus C18 FF-MTO + porcine liver 0.1M KH2PO4/H3PO4
(pH = 6.0) 1 N HCl/MeOH n.d.(4)
Sep-Pak-Plus C18 FF-MTO + porcine liver 0.1M KH2PO4/HCl 1 N HCl/MeOH 17 ±16
(1)number of independent experiments = 3
(2)single experiment
(3)Typical extraction procedure: double incubation in ultrasonic bath each for 10 minutes. Collecting the supernatant after centrifugation and HPLC-
measurement afterwards
(4)Not detectable.
Klejdus et al. [23]. The cycle time was 10 minutes and just
o n ec y c l ef o re a c hs a m p l ew a sp e r f o r m e d .
To sum up, each 0.5g MTO-containing tissue was treated
4 times for 1 hour with ultrasound in the extraction mixture
(500μLwater ,50μLascorbicacid(20%)incitratebuﬀer(pH
3.0) 200μL methanole (MeOH), 200μL formic acid, 100μL,
20% trichloroacetic acid, 400μL chloroform) followed by
centrifugation for 10 minutes at 8000 ×G( J o u a nM R2 3I ,
Germany). The combined supernatant was concentrated via
a Bond Elut Plexa (200mg, 6mL, Varian, Darmstadt, Ger-
many)cartridgeafterconditioning withacetonitrile(MeCN)
and 2% formic acid in water. The analyte was eluted with
5mL 2% formic acid in MeCN and dried under airstream.
The water resolved residue was measured by HPLC as
described above to display the eﬃciency of the extraction.
3. Results and Discussion
3.1. Optimization of the Extraction. In terms of drug delivery
with nanoparticles, only traces of MTO are embedded in
diﬀerent tissues so that the whole organ has to be processed.
The extraction of MTO using 1N hydrochloric acid (HCl),4 Journal of Biomedicine and Biotechnology
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Figure 2: Extraction eﬃciency: extraction with: 500μLw a t e r ,
200μLM e O H ,5 0μL ascorbic acid (20%) in citrate buﬀer (pH 3.0),
200μL formic acid, 100μL 20% trichloroacetic acid, and 400μL
chloroform in an ultrasonic bath. Recovery rate in dependence to
multiple extractions. 4 fold extraction is nearly quantitative. Each
reading point was measured in triplicate.
M e O H / 1NH C l( 5 0:5 0v / v ) ,o r1NH C l / M e C N( 9 0:1 0v / v )
was eﬃcient for extracting pure MTO (Table 1). When it was
bound to FF, the yield decreased signiﬁcantly. Since a one-
phase-extraction led to turbid, protein-rich supernatants,
protein precipitation by trichloroacetic acid (TCA) as well as
Carrez-clearing[24]wereused.Unfortunately,bothmethods
did not show promising results. Especially, Carrez-clearing
even leads to a blue coprecipitate of MTO.
A new point of view oﬀered the extraction mode of Lu
et al. [19] with a two-phase-extraction system to separate
interfering lipophilic substances in organs, especially liver
tissue. This method gave also the possibility to precipitate
the protein fraction and save MTO from decomposition.
Nevertheless, we modiﬁed this method because more tissue
and less MTO required an optimization. We used homog-
enization for 1 minute via Ultra Turrax (Ika) to dehisce
the cell membranes prior to sonication. Simple vortexing
and just one single extraction cycle obtained only 26%
recovery (Table 2). Ultrasonic extraction was superior to
simple vortexing, and multistep-extraction even increased
the eﬃciency. A 4-fold extraction each for 1 hour was nearly
quantitative (88 ±4%) (Figure 2).
Of course, the accelerated solvent extraction (ASE)
(Table 2) method led to high extraction rates in short time
but this is very expensive. Moreover, ASE tends to require
also a useful SPE processing afterwards.
3.2. Combination of Extraction and Cartridge Procedure. To
quantify the MTO amount of a whole organ, a useful
SPE method was necessary. Unfortunately all the extraction
modes described in Table 1 lead to turbid, protein-rich
supernatants clogging the SPE cartridge. Using the RP-
18 Cartridge (Sep-Pak-Plus C18, 360mg, Waters) and a
standard elution procedure with water and MeOH, recovery
of MTO was not suﬃcient although pretesting with pure
MTO gave promising results (>90%) (Table 3). A recovery
rate of 76% by extraction of MTO in porcine liver tissue with
phosphoric acid was adequate (Table 3). It is also possible
to extract, ﬁxate, and elute MTO bound to FF when using
phosphoric acid or phosphate; but in the presence of liver
tissue, the recovery of MTO connected to FF was scarce
after the elution from the cartridge. In that case, extraction
mixtures lead at the most to 17% recovery and almost no
reproducibility. This was also true when hydrochloric acid
was used for the extraction. The FF dissolved under these
conditions and interestingly only traces of MTO could be
detected, no matter what kind of conditioning mode was
used for the SPE.
The choice of the right cartridge was essential. The
widespread used RP-18 cartridge seemed to be not useful
in our context. Most of the tested cartridges perform the
ﬁxation and elution of released MTO bound to FF, but in
presence of liver tissue only Varian Bond Elut Plexa gave
appropriate yields with more than 80% recovery (Table 4).
To sum up, the whole method entails a 1-hour ultrasonic
extraction repeated 3× of tissue with the 2-phase extraction-
solution followed by concentration and puriﬁcation via
Varian Bond Elut Plexa cartridge and the consecutive HPLC
measurement (Figure 3).
3.3. Validation Procedure
3.3.1. Selectivity. Chromatograms obtained from processed
blank liver tissue did not show interfering peaks at the
retention time of pure MTO measured by HPLC as seen
in Figure 4. Selectivity was proved from 6 blank animals
using their liver, lung, kidneys and muscle tissue. Each
extraction was measured 5 times via HPLC. The results have
to be observed in detail. Kidney, lung, and muscle tissue
show a baseline chromatographic resolution of at least 1.5
from all other sample components and can be declared as
fully separated. This criterion cannot be achieved for liver.
The deﬁcient baseline resolution could inﬂuence the analyte
response. Experiments were performed to evaluate to what
extend the impurity peak will aﬀect the ﬁnal assay result. 6
extraction solutions doted with MTO at the same amount,
as the impurity peak is responding to (100ng/mL), were
concomitant analysed with identical amount of 100ng/mL
MTO in mobile phase solution. T-test of these 2 diﬀerent
population means gave the result that the impurity peak
inﬂuences the respond signiﬁcantly. To meet the speciﬁc
criteriathatnonseparableimpuritypeaksinﬂuencetheresult
at most for 0.5% MTO [25], amounts more than 250ng/mL
can seriously be quantiﬁed.
3.3.2. Linearity and Lowest Limit of Quantiﬁcation (LLOQ).
5 independent sets of calibration standards including
blank samples have been prepared comprising values from
10ng/mL to 20000ng/mL pure MTO (0, 10, 20, 50, 100,
1000, 2000, 5000, 10000, 20000ng/mL); the 10ng/mL stan-
dard was detected as the Lowest Limit of Quantiﬁcation
(LLOQ). The maximum deviation of the back calculated
valuesfortheLLOQwas11.8%and13.4%forreadingpointsJournal of Biomedicine and Biotechnology 5
Tissue sample
Extraction solution for 0.5gtissue:
500μLw a t e r ,5 0μL ascorbic acid (20%) in citrate buﬀer (pH 3), 200μLM e O H ,
200μL formic acid, 100μL 20% trichlorous acetic acid, 400μL chloroform
Homogenisation for 1min via Ultra Turrax
Soniﬁcation for 1h
Centrifugation: 8000 × G
Combined aqueous phases
Process repeated 3 times
Solid residue +
chloroform phase
HPLC
measurement
Enrichment on
Bond Elut Plexa
cartridge
Elution with
1mLformic
acid (2%)
in MeCN
Drying/resolvation in
HPLC solvent
Figure 3: Flow chart of the whole method how to determine MTO in tissue: ﬂow chart of the whole method how to determine MTO in
tissue.
Table 4: Recovery of MTO after extraction of diﬀerent matrices using diﬀerent cartridges. Results vary extraordinarily, FF-bound MTO in
liver tissue requires special solid phase.
Matrix Cartridge Cartridge treatment after extraction(1) Recovery [%]
FF-MTO Chromabond HR-X (Machery&Nagel) Water, MeOH 21,2%
FF-MTO Chromabond HR-X (Machery&Nagel) 1N HCl, MeOH 22%
FF-MTO Oasis MCX (Waters) HCOOH (2%), MeOH, Elution with
5% NH3
0,9%
FF-MTO LiChrolut En (Merck) Water, MeOH 89 ±5
FF-MTO
1: Bond Elut PPL (Varian) MeOH, HCOOH (2%). 1:75%
Rinse with HCOOH (2%).
2: Bond Elut Plexa (Varian) Elution with (2%) HCOOH in 2:81%
MeOH.
FF-MTO + 0.5g
porcine Liver Sep-Pak-Plus C18 (Waters) MeOH, 1N HCl 7 ± 2
FF-MTO + 0.5g
porcine Liver LiChrolut En (Merck) Water, MeOH n.d.(2)
FF-MTO + 0.5g
porcine Liver
1: Bond Elut PPL (Varian) MeOH, HCOOH (2%).. 1:31%
Rinse with HCOOH (2%).
2: Bond Elut Plexa (Varian) Elution with (2%) HCOOH in 2:86%
MeOH
(1)Threetimesextractingwith:500μLwater,200μLM eOH,50μLascorbicacid(20%)incitratebuﬀer(pH3.0),200μLformicacid,100μL20%trichloroacetic
acid, 400μL chloroform in an ultrasonic bath.
(2)n.d.: not detectable. MTO could not be ﬁxated on the cartridge.6 Journal of Biomedicine and Biotechnology
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Figure 4: (a) HPLC-chromatogram of pure mitoxantrone (MTO
200ng/mL), (b) HPLC-chromatogram of processed blank liver
tissue. No interfering peak at the retention time is determined for
MTO.ChromatographicConditions:3.0×100mmX-BridgePhenyl
column (Waters, Germany), ﬂow: 1mL/min, mobile phase: buﬀer
(80nM sodium formate and formic acid, pH 3.0) and methanol
(80:20v/v). Column temperature 55◦C, injection volume 50μL,
UV-detection: 254nm. (c) HPLC-chromatogram of processed liver
tissue containing MTO bound to ferroﬂuids. MTO is at retention
time 9,77.
unlike the LLOQ. The deviation of each reading point meets
the FDA speciﬁcation for linearity of ±15% (LLOQ ±20%).
For quantiﬁcation of unknown samples, a linear equation
without any weighting was used. Goodness of ﬁt was not
evaluated, because the correlation coeﬃcient with more than
0.999guaranteesasuﬃcientlinearcorrelationbetweenMTO
concentration and analytical response over the whole range
(Figure 5). The LLOQ was determined according to the
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Figure 5: Mitoxantrone standard curve.
guidelines of FDA for bioanalytical method validation and is
deﬁned as the 5-time response compared to blank samples.
This applies to the level of 10ng/mL [21].
3.3.3.Precision. Intraassayprecisionisdeterminedfor3con-
centrations of pure MTO (5000; 10000 and 15000ng/mL).
Each level was measured 5 times. The Level for 5000ng/mL
gave 1.0% relative standard deviation, the according data
for the 10000ng/mL and 15000ng/mL levels are 0.9% and
1.0%, respectively. Interassay precision was performed on 5
diﬀerent days for the same values mentioned for intraassay.
The relative standard deviations were: 1.4% for 5000ng/mL,
8.6% for 10000ng/mL and 2.4% for 15000ng/mL.
3.3.4. Accuracy. Intraassay accuracy is determined for 3
concentrations of unbound MTO (5000, 10000, and
15000ng/mL). Each level was measured 5 times. The Level
for 5000ng/mL gave a deviation of the mean from the true
value of 1.4%; for 10000ng/mL measurements gave 1.7%
and 1.8% for 15000ng/mL, respectively and so meet the
criteria which are 80–120% for the target concentration.
The same experiments have been performed as interassay
accuracy. Measurements mentioned above were arranged on
5d i ﬀerent days. The accuracy values (deviation of the mean
from the true value) were 2.1% for 5000ng/mL, 5.6% for
10000ng/mL, and 0.3% for 15000ng/mL.
3.3.5. Recovery Rate. Liver tissue was used exemplarily to
evaluate the recovery rate with variable tissue and MTO
amounts. The recovery rate of MTO in 5g liver tissue was
evaluated for 3 diﬀerent MTO concentrations. Series A was
doped with 25μg, series B contained 2.5μg, and series C
0.25μg MTO bound to FF. The experiments were performed
in 3 independent experiments and measured in triplicate.
The total recovery rate (extraction and SPE) for MTO in
liver tissue for series A (5000ng/g) was 76 ± 2% for series
B (500ng/g) 67 ±5 %a n df o rs e r i e sC( 5 0n g / g )6 8± 4%.
The experiments were performed for 3 independent
samples keeping in mind that the recovery can be diﬀerent
when using other tissues than liver. For biodistribution,
recovery depends on the total weight of organs. The bigger
theorgansarethemoreMTOcanbeextractedincomparison
to smaller organs having the same drug concentration.Journal of Biomedicine and Biotechnology 7
Table 5: Amount of MTO in diﬀerent tissues after intravenous
application of ferroﬂuid-bound MTO. New Zealand White rabbits
(n = 5) were treated with 10% of the systemic necessary dose
(10mg/m2 body surface).
Tissue Detected MTO [ng] per g tissue(1)
Lung 30 ±17
Liver 89 ±22
Kidneys 537 ±94
Muscle tissue 1.4 ±0.7(2)
(1)deviation calculated as sem (standard error of the mean)
(2)concentration below the quantitation limit.
3.3.6. Stability. Processing the MTO-containing samples, the
extraction from tissue material and SPE afterwards can lead
to fragmentation of the analyte. We proved the stability of
MTO by treating MTO and MTO bound to ferroﬂuids in the
extraction solution (12500ngMTO/mL) for 3 hours in an
ultrasonicbath.ReprocessingusingBondElutPlexa(Varian)
cartridges lead to recovery of 85±1% (n = 3) in case of pure
MTO samples and 89 ± 1% (n = 3) in case of ferroﬂuid-
bound MTO samples. The deﬁcit of the MTO amounts is
owed to the cartridge procedure.
3.4. Pilot Experiments in order to Perform Biodistribution
Studies. We used the method, described above with 4 ×
1 hour ultrasonic extraction (Figure 3), to measure the
biodistribution of MTO in rabbits (New Zealand White,
Charles River Corp., Germany) after intravenous (i.v.)
application within a pilot study. For the experiments, New
Zealand White Rabbits were used in accordance with the
responsibleauthority(RegierungvonMittelfranken,request:
54-2531.31-27/06 approved in April 2007). The animals,
weighing about 4.5–5.2kg, were treated with ferroﬂuid-
boundMTOcontainingadrugamountof10%totheregular
systemic dose which requires 10mgMTO/m2 body surface.
After 24 hours, the animals were sacriﬁced and organs
harvested. Complete organs of liver, lung, kidneys, and a
muscle tissue sample were processed and treated in a 100mL
glass ﬂask (Duran, Germany) with the respective amount of
extraction solution increased to the amount for the weight of
the entire organ as described above followed by SPE.
3.5. Suitability of the Method to Quantify Ferroﬂuid-Bound
MTO. The application of this newly developed method
has been proven suitable in a starting in vivo pilot study
with New Zealand White rabbits. First experiments with
ferroﬂuid-bound MTO showed that the highest enrichment
could be found in the kidneys. The results exhibited the wide
range of MTO amounts in diﬀerent tissues and proved the
suitability of the method for diﬀerent kinds of biological
materials (Table 5).
4. Discussion
To the best of our knowledge, none of the existing protocols,
concerning the analysis of mitoxantrone in tissues, have been
feasible for our approach of ferroﬂuid-bound MTO. More-
over, there is especially a lack of techniques to detect small
amountsinlargescaledtissues.Withourmethodconnecting
eﬃcient extraction procedures with enrichment strategies
towards detectable extraction solutions, we are able to per-
form biodistribution studies. Monitoring MTO enrichment
in diﬀerent tissues in case of FF-bound drug delivery and
overlapping the results with magnetorelaxometric measure-
ments, complex biodistribution patterns after application of
MTO-bound iron oxide nanoparticles become low hanging
fruits. Current developments in chemotherapy increasingly
base on nanoscaled delivery systems. Nanoparticles, lipo-
somes, encapsulations, micelles, and other nanostructures
carrying chemotherapeutics require newly developed or
modulated analytical methods. With this protocol in hand
further detailed analytical instructions can be developed for
adsorptive drug delivery systems using well-established and
prevalent applied HPLC.
5. Conclusion
Here we present an easy-to-perform and versatile appli-
cable new method to determine even small amounts of
mitoxantrone, regardless if it is in pure or ferroﬂuid-bound
condition in tissues or other biological matrices. Established
procedures have not been useful in our context to detect
mitoxantrone, especially in presence of FF and contained in
tissue samples weighing more than 100g which especially is
necessary for medical application studies in cancer research.
We applied this method to evaluate the biodistribution
of MTO in rabbit tissue. Within ﬁrst experiments, we
could easily perform the measurements of whole organs
and showed the applicability of this new method and its
widespread possibilities and analytical applications.
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